MONMOUTH JUNCTION, N.J.,
Aug. 6, 2014 /PRNewswire/
-- CytoSorbents Corporation (OTCQB: CTSO), a critical care
immunotherapy company commercializing its European Union approved
CytoSorb® blood filter to treat life-threatening illnesses in the
intensive care unit, will report Q2 2014 financial results after
the market close on Tuesday, August
12, 2014.
CytoSorbents' management will host a live conference call and
presentation webcast that will recount both operational and
financial progress during Q2 2014 and answer pre-submitted
questions as time permits.
Conference Call Details:
Date: Tuesday, August
12, 2014
Time: 4:15 PM Eastern
Participant Dial-In: 913-312-1269
Live Presentation Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1041083
It is recommended that participants dial in approximately 10
minutes prior to the start of the call. There will also be a
simultaneous live webcast of the conference call that can be
accessed through the following audio feed link:
https://viavid.webcasts.com/starthere.jsp?ei=1041083
An archived recording of the conference call will be available
under the Investor Relations section of the Company's website
at http://www.cytosorbents.com/invest.htm
Investors are encouraged to submit their questions in advance as
soon as possible to Ms. Amy Vogel at
avogel@cytosorbents.com
About CytoSorbents Corporation
CytoSorbents
Corporation is a critical care focused immunotherapy company using
blood purification to modulate inflammation -- with the goal of
preventing or treating multiple organ failure in life-threatening
illnesses. Organ failure is the cause of nearly half of all deaths
in the intensive care unit, with little to improve clinical
outcome. CytoSorb®, the Company's flagship product, is approved in
the European Union as a safe and effective extracorporeal cytokine
adsorber, designed to reduce the "cytokine storm" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury, and pancreatitis. These are conditions where the risk of
death is extremely high, yet no effective treatments exist.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. CytoSorbents has numerous products under
development based upon this unique blood purification technology,
protected by 32 issued US patents and multiple applications
pending, including HemoDefend™, ContrastSorb, DrugSorb, and others.
Additional information is available for download on the Company's
website: http://www.cytosorbents.com/
Forward-Looking Statements
This press release includes
forward-looking statements intended to qualify for the safe harbor
from liability established by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ
materially from those anticipated. These statements are based on
management's current expectations and assumptions and are naturally
subject to uncertainty and changes in circumstances. We caution you
not to place undue reliance upon any such forward-looking
statements. Actual results may differ materially from those
expressed or implied by the statements herein. Risk factors are
detailed in the Company's Form 10-K filed with the SEC on
March 31, 2014, which is available at
http://www.sec.gov.
Please Click to Follow us on Facebook and
Twitter
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
SOURCE CytoSorbents Corporation